Engineering CAR T Cells to Resist Tumor Immune Suppression
CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models
-
1
Genetically engineered CAR T cells can evade tumor immune suppression, potentially extending therapies to solid cancers.
-
2
Disabling EP2 and EP4 receptors in CAR T cells allows them to remain active in PGE2-rich tumor environments.
-
3
The modified CAR T cells showed improved tumor control in mouse models of pancreatic cancer, melanoma, and mesothelioma.
-
4
The enhanced persistence of EP2/EP4-deficient CAR T cells, rather than increased killing capacity, contributes to better outcomes.
-
5
The researchers plan to test this strategy in clinical studies, starting with lymphoma before moving to solid tumors.
